Literature DB >> 1835140

Immune response to hepatitis B vaccine in premature neonates.

S Chawareewong1, A Jirapongsa, K Lokaphadhana.   

Abstract

The immunogenecity of a recombinant yeast-derived hepatitis B vaccine in 25 premature infants who were born to HBsAg negative mothers was studied. The gestational ages were 28-37 weeks and birth weights were 1300-2000 grams. Seroconversion occurred in 22 infants, the anti HBs titers varied between 50 and 13,470 IU/L (Geometric mean titer = 542 IU/L). Seroconversion rate = 88%. The response did not vary with gestational age, birth weight or illness status.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1835140

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN： 0125-1562            Impact factor:   0.267


  9 in total

1.  Immunogenicity of plasma-derived hepatitis B vaccine in preterm infants.

Authors:  K R Shankar; R K Dhiman; A Narang
Journal:  Indian J Pediatr       Date:  2000-01       Impact factor: 1.967

2.  Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth.

Authors:  N Linder; R Handsher; B German; L Sirota; M Bachman; S Zinger; E Mendelson; A Barzilai
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-07       Impact factor: 5.747

3.  Hepatitis B vaccination in preterm infants.

Authors:  F Y Huang; P I Lee; C Y Lee; L M Huang; L Y Chang; S C Liu
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

4.  Immunogenicity of hepatitis B vaccine in preterm infants.

Authors:  O Blondheim; D Bader; M Abend; M Peniakov; D Reich; I Potesman; R Handsher; I Gidoni; N Linder
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

Review 5.  Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability.

Authors:  Carl T D'Angio
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

6.  Hib vaccination in infants born prematurely.

Authors:  P T Heath; R Booy; J McVernon; J Bowen-Morris; H Griffiths; M P E Slack; A C Moloney; M E Ramsay; E R Moxon
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

7.  Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/haemophilus influenzae type B vaccine.

Authors:  Felix Omeñaca; Jose Garcia-Sicilia; Reyes Boceta; Pilar García-Corbeira
Journal:  Infect Dis Obstet Gynecol       Date:  2010-04-12

Review 8.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Response to the complete hepatitis B vaccine regimen in infants under 12 months of age: a case series.

Authors:  Alexandre Lopes Miralha; Adriana Malheiro; Angélica Espinosa Miranda; George Williams Rutherford; Maria das Graças Costa Alecrim
Journal:  Braz J Infect Dis       Date:  2012-12-29       Impact factor: 3.257
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.